Highlights 

  • NICE issues draft guidance recommending AUCATZYL (obe-cel) for adult patients with relapsed or refractory B-cell precursor ALL. 
  • AUCATZYL will be made available through routine NHS commissioning in England and Wales. 
  • The recommendation follows MHRA’s conditional marketing authorisation granted in April 2025. 
  • FELIX Phase 1b/2 results underpin the decision, showing meaningful clinical activity in adult r/r B-ALL. 
  • Autolus plans immediate launch in England and Wales and aims for Scottish access next. 

Autolus Therapeutics plc (NASDAQ:AUTL) announced that the National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending AUCATZYL (obecabtagene autoleucel) for adults aged 26 years and older with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). With this decision, AUCATZYL will be available through routine commissioning by the UK National Health Service in both England and Wales. 

The company expects to begin launching the therapy immediately, marking a key moment for patients who have long faced limited treatment options. Autolus also intends to pursue patient access through the Scottish Medical Consortium to ensure broader UK availability. 

Dr. Christian Itin, CEO of Autolus, stated that the recommendation represents a meaningful step forward for eligible r/r B-ALL patients, many of whom have few effective alternatives. He acknowledged the vital contribution of UK clinical centres and patients who participated in the therapy’s development. 

Regulatory Path and Evidence Supporting Approval

AUCATZYL previously received conditional marketing authorisation from the UK Medicines and Healthcare products Regulatory Agency in April 2025. This authorisation was based on findings from the FELIX study, an open-label, multicentre, single-arm trial assessing the therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia. 

Stakeholders across the patient advocacy community welcomed the NICE draft guidance. Leaders from Anthony Nolan, Leukaemia Care and Leukaemia UK emphasized the high unmet need in r/r B-ALL and highlighted that access to this CAR T therapy can offer a new option for individuals with an aggressive and life-threatening disease. These organisations also underscored the significance of patient involvement in the NICE evaluation process.

About AUCATZYL andAutolusTherapeutics 

AUCATZYL is an autologous CD19 CAR T cell therapy engineered with a proprietary construct designed to overcome limitations observed in earlier CD19-directed CAR T therapies. Its fast target binding off rate is intended to reduce excessive T cell activation while maintaining potent activity against leukemic cells. 

The therapy was first approved by the US FDA in November 2024 for adult r/r B-ALL and subsequently received conditional authorisation from both the MHRA and the European Medicines Agency in 2025. 

Autolus Therapeutics plc is an early commercial-stage biopharmaceutical company developing next-generation programmed T cell therapies for cancer and autoimmune disease. Its proprietary T cell programming platforms are designed to enable precise targeting, improved persistence, and controlled activity across multiple therapeutic areas. 

Conclusion 

The NICE draft recommendation for AUCATZYL represents a substantial advancement for adults living with relapsed or refractory B-cell precursor ALL in England and Wales. With imminent NHS availability and supportive evidence from the FELIX study, the therapy offers a new pathway for patients with limited options. The decision strengthens Autolus’ presence in the UK and reinforces the growing role of next-generation T cell therapies in addressing difficult-to-treat hematologic cancers. 

Also read - Sanofi (NASDAQ:SNY): EU Clears Dupixent as First Targeted CSU Treatment in a Decade